Merck Chief Medical Officer Michael Rosenblatt recently caused quite a stir when he suggested that a lot of academic research work in the drug field is a mess, urging that investigators be forced to return at least some of their funding if industry scientists can’t reproduce their work.
And now, Rosenblatt will get to explain his position on a face-to-face basis.
Cambridge, MA-based Flagship Ventures, which has been soaking up academic research in its quest to start up a string of new biotechs, has named Rosenblatt as its very first CMO. And he’s been tapped to play a leading role in spawning a new wave of upstarts at Flagship.
Rosenblatt is joining a long lineup of top biopharma R&D execs to turn in prominent roles at the world’s top companies to jump into the venture/biotech startup field. That list includes Briggs Morrison (AstraZeneca), JC Gutierrez-Ramos (Pfizer), Doug Williams (Biogen) and more.
He’s had a long and distinguished career, and Rosenblatt is allied with some deep pockets, so chances are he’ll be welcome with open arms. His resume includes: Dean of Tufts University School of Medicine; Robert Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; President, Harvard Faculty Dean and Senior Vice President for Academic Programs of Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.Free Subscription